Muscarinic acetylcholine receptor M1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Muscarinic acetylcholine receptor M1 as ChEMBL target CHEMBL276, mapped to UniProt P08482. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Muscarinic acetylcholine receptor M1 matters
Muscarinic acetylcholine receptor M1 is reviewed as Muscarinic acetylcholine receptor M1 (UniProt P08482); the current evidence base includes 23 approved drugs, 2103 compounds, and 274 assays, with lead potency reaching pChEMBL 11.0.
Muscarinic acetylcholine receptor M1 Sequence length is 460 aa.
Review this target as Muscarinic acetylcholine receptor M1, mapped to UniProt P08482. Sequence length is 460 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 23 approved drugs, 2103 compounds, and 274 assays for this target. The dominant activity type is KI. CHEMBL21905 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL21905 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Muscarinic acetylcholine receptor M1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P08482, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL21905
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL21812
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL3298595
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL320611
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL3298599
|
10.4 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
XANOMELINE
CHEMBL21536
|
2024 |
|
|
TIOTROPIUM BROMIDE
CHEMBL3545181
|
2004 |
|
|
SOLIFENACIN
CHEMBL1734
|
2004 |
|
|
TOLTERODINE
CHEMBL1382
|
1998 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
METHACHOLINE
CHEMBL978
|
1986 |
|
|
SCOPOLAMINE
CHEMBL569713
|
1979 |
|
|
OXYBUTYNIN
CHEMBL1231
|
1975 |
|
|
PILOCARPINE
CHEMBL550
|
1974 |
|
|
CARBACHOL
CHEMBL14
|
1972 |
|
|
ATROPINE
CHEMBL517712
|
1960 |
|
|
BENZTROPINE
CHEMBL1201203
|
1954 |
|
|
DICYCLOMINE
CHEMBL1123
|
1950 |